285 related articles for article (PubMed ID: 28846831)
1. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
2. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
[TBL] [Abstract][Full Text] [Related]
3. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
5. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
[TBL] [Abstract][Full Text] [Related]
6. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
7. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
Lu G; Lin J; Bui K; Curnutte JT; Conley PB
Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
[TBL] [Abstract][Full Text] [Related]
8. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
Brinkman HJM; Zuurveld M; Meijers JCM
Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
[TBL] [Abstract][Full Text] [Related]
10. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
11. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
12. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Frost C; Garonzik S; Shenker A; Barrett YC; LaCreta F
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
[TBL] [Abstract][Full Text] [Related]
13. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
14. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
Nagalla S; Thomson L; Oppong Y; Bachman B; Chervoneva I; Kraft WK
Clin Transl Sci; 2016 Jun; 9(3):176-80. PubMed ID: 27170068
[TBL] [Abstract][Full Text] [Related]
15. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Frost C; Nepal S; Wang J; Schuster A; Byon W; Boyd RA; Yu Z; Shenker A; Barrett YC; Mosqueda-Garcia R; Lacreta F
Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
[TBL] [Abstract][Full Text] [Related]
17. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
[TBL] [Abstract][Full Text] [Related]
18. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
19. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
Schultz NH; Lundblad R; Holme PA
J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
[TBL] [Abstract][Full Text] [Related]
20. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]